NPY and Obesity: Thus, since the trend in medical care is moving toward more personalized pharmacotherapy, the blockade of peripheral Y2-receptors could be targeted for the treatment of the obesity accompanied with elevated noradrenergic NPY levels (e.g., during stress or genetic NPY overexpression) in energy rich environment.